Dialysis Centers in the US: Market Size, Businesses & Forecast 2026

The dialysis centers industry in the United States comprises specialized facilities providing vital life-support treatments to patients with end-stage kidney disease (ESKD). Industry operations are intensely focused on providing in-center hemodialysis and supporting a growing base of home-based modalities like peritoneal dialysis. Financial expansion is tightly linked to federal health allocations, highlighted by a total FFS Medicare outpatient dialysis spend of 8.1 billion USD in 2023 (Medicare Payment Advisory Commission). The industry's overarching trajectory remains steady due to an aging population, despite an structural shift of patient enrollments away from traditional fee-for-service

Industry snapshot

Key public data points

Historical & forecast

Get in touch and our analysts will be happy to help with custom market sizing, deeper segmentation, supplier detail or a bespoke study built for you.

What does the Dialysis Centers in the US industry cover?

The industry comprises outpatient establishments primarily engaged in administering kidney dialysis treatments to patients with severe, permanent kidney failure, known as end-stage kidney disease (ESKD). These facilities offer specialized clinical environments where waste products and excess fluids are artificially filtered from the blood when the kidneys can no longer function adequately. Services are categorized into in-center hemodialysis and home-based training and support, which includes both home hemodialysis and peritoneal dialysis.

• •Primary medical services revolve around clearing toxins via artificial dialyzer membranes, usually prescribed three times per week for in-center patients.
• •Scope includes the provision of essential End-Stage Renal Disease (ESRD) related drugs and biologics to manage conditions like anemia and bone disease.
• •Home dialysis monitoring and clinical training for independent treatments are recognized components within the outpatient facility framework as of 2025 guidelines.

Who operates in the industry and how is it structured?

The industry is highly concentrated and dominated by a few massive corporate operators that control the vast majority of freestanding clinics across the country. Market dynamics are heavily impacted by federal reimbursement policies since the federal government acts as the primary payer for the majority of dialysis patients. Operators manage immense networks of regional clinics to achieve the economies of scale necessary to absorb low-margin government reimbursement structures.

• •Freestanding facilities handle the vast majority of outpatient treatments compared to hospital-based programs.
• •The market is highly integrated with nephrology practices and specialized laboratory networks to coordinate complex patient journeys.
• •According to the MedPAC March 2025 Report, Fee-for-Service (FFS) Medicare treatments experienced an 11 percent decline between 2022 and 2023 due to a structural migration of beneficiaries toward Medicare Advantage (MA) plans.

What drives demand in the industry?

Demand for outpatient dialysis services is driven entirely by the clinical prevalence of ESKD and chronic kidney disease (CKD) within the population. Underlying medical conditions, particularly diabetes and hypertension, serve as the primary contributors to progressive kidney failure. The aging demographic profile of the United States further accelerates the patient volume, as CKD rates rise sharply in older cohorts.

• •According to the Centers for Disease Control and Prevention (CDC) 2026 reporting, approximately 37 million US adults (14 percent) are estimated to have chronic kidney disease.
• •United States Renal Data System 2025 data indicates that about 831,000 people in the US are living with ESKD, with 67 percent of them relying directly on active dialysis treatments.
• •Among adults 18 years and older, diabetes and high blood pressure remain the predominant medical causes of underlying kidney failure.

Who are the notable companies in the industry?

The US dialysis market exhibits a clear duopolistic structure, where two major multinational operators command a massive share of the nationwide clinic footprint. Remaining market share is split between a secondary tier of mid-sized regional providers, non-profit operators, and hospital-based outpatient networks. Competition centers on clinical quality metrics, geographical access, and preferred provider relationships with health insurance networks.

• •DaVita Inc. stands as a premier market leader, operating 2,666 outpatient dialysis centers within the United States as of March 2026.
• •Fresenius Medical Care AG maintains a massive competing presence across the United States, operating as an integrated provider of both dialysis services and specialized medical equipment.
• •U.S. Renal Care, Inc. operates as a substantial national provider, managing hundreds of clinics across multiple states.
• •American Renal Associates and Innovative Renal Care represent notable corporate competitors operating multi-state clinical footprints across the country.

What are the recent trends and outlook?

The industry is experiencing a deliberate push toward expanding home dialysis modalities, which offer patients greater flexibility and quality-of-life benefits. Technological innovation is focused on improving home hemodialysis machines and clinical decision-support software. Financial performance remains tight, but has shown subtle margin improvements as labor shortages and clinical input costs began to normalize coming out of historical highs.

• •Peritoneal dialysis (PD) stands out as the most common form of home dialysis, utilizing the patient's own abdominal lining as a natural filter.
• •The MedPAC March 2025 Report detailed that the FFS Medicare margin for freestanding facilities recovered slightly to negative 0.2 percent in 2023, up from negative 1.1 percent in 2022.
• •Total Medicare spending for outpatient dialysis items and services, including new add-on items like the Tablo Hemodialysis System, reached $8.1 billion in 2023.

How is the industry regulated?

Operators are subject to extensive federal and state oversight, with the Centers for Medicare & Medicaid Services (CMS) serving as the primary regulator. Facilities must maintain strict compliance with Conditions for Coverage to receive Medicare program reimbursements. Under performance-based oversight frameworks, reimbursement updates are directly tied to clinical outcomes and quality achievements.

• •CMS utilizes the ESRD Quality Incentive Program (QIP), which penalizes underperforming facilities with a payment rate reduction of up to 2 percent.
• •CMS adjusts its Prospective Payment System (PPS) base rate using localized geographic factors and an ESRD-specific wage index; for 2025, the base payment rate was set at $273.82 per treatment.
• •For calendar years 2024 through 2026, CMS mandates a transitional pediatric ESRD add-on payment adjustment equal to 30 percent of the per-treatment amount to support youth-centered clinical operations.

Government, statistical and trade sources used for this Claight analysis.

• Medicare Payment Advisory Commission (MedPAC) Report to the Congress: Medicare Payment Policy March 2025 ·
• Centers for Disease Control and Prevention (CDC) Chronic Kidney Disease in the United States 2026 ·
• United States Renal Data System (USRDS) 2025 Annual Data Report ·
• DaVita Inc. Form 10-K Annual Report 2025 ·
• Centers for Medicare & Medicaid Services (CMS) End-Stage Renal Disease Prospective Payment System Final Rule 2025